HEMATOLOGICAL MALIGNANCIES
Clinical trials for HEMATOLOGICAL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGICAL MALIGNANCIES trials appear
Sign up with your email to follow new studies for HEMATOLOGICAL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Lab-Grown stem cells could speed recovery after transplant for blood cancers
Disease control CompletedThis Phase 3 trial tested a new stem cell product called NiCord (omidubicel) for people with blood cancers like leukemia and lymphoma. NiCord is made by growing stem cells from donated umbilical cord blood in a lab, so patients get more cells. The study compared NiCord to standar…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE3 • Sponsor: Gamida Cell ltd • Aim: Disease control
Last updated Jun 23, 2026 23:35 UTC
-
New drug combo could make blood cancer transplants safer and more available
Disease control CompletedThis study tested whether giving the drug cyclophosphamide after a stem cell transplant could help prevent a serious complication called graft-versus-host disease (GVHD) in 78 blood cancer patients. The approach aimed to make transplants from less-than-perfect donors as safe and …
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
New drug cocktail shows promise for tough blood cancers
Disease control CompletedThis phase 2 trial tested a combination of two immunotherapy drugs, pembrolizumab and vibostolimab (called MK-7684A), in 192 people with blood cancers like lymphoma and multiple myeloma that had come back or stopped responding to treatment. The main goals were to see if the drug …
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant using a drug called cyclophosphamide to lower the risk of graft-versus-host disease (GVHD) in people with high-risk blood cancers like leukemia and lymphoma. The goal was to improve survival one year after transplant. The trial in…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
Blood cell study aims to predict transplant complications
Knowledge-focused CompletedThis study looked at 57 people who had a stem cell transplant for blood cancer. Researchers wanted to see if certain immune cells (iNKT cells) could help predict the risk of graft-versus-host disease (GVHD), a serious side effect. They measured these cells in the blood and the tr…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:08 UTC
-
PET scans tested for rare fungal infection in cancer patients
Knowledge-focused CompletedThis study looked at whether a special type of scan (PET scan) can help doctors decide how to treat a rare fungal infection in the liver and spleen. The infection happens in people with weakened immune systems, such as those with blood cancer or who had a stem cell transplant. Th…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:53 UTC
-
Gene type may affect how cancer drug works in patients
Knowledge-focused CompletedThis study looked at how the cancer drug belinostat is processed in the body by people with advanced solid tumors or blood cancers. Researchers wanted to see if a person's genetic makeup (specifically the UGT1A1 gene) changes how the drug works or causes side effects. The study i…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1 • Sponsor: Acrotech Biopharma Inc. • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:08 UTC